Event Type: State-wide seminar series

Educational Molecular Tumour BoardMelanoma Institute Australia – Personalised Immunotherapy ProgramPlease join us for this Educational Molecular Tumour Board Session with presenters from the Melanoma Institute Australia giving insight into their Personalised Immunotherapy Program. This presentation will cover:– The background around genomic, transcriptomic and tumour immune profiling as biomarkers of response to immunotherapies.– Biomarker multidisciplinary discussion … Read more

“Burning Issues in Radiotherapy Research”This session will provide a great opportunity to explore radiation oncology as a vibrant research sphere that researchers may never have considered before. Hear about the consumer experience, the role of biology in radiation research, the examination of technology and the role of radiation oncology clinical trials. SpeakersAssociate Professor Eric Hau. Radiation … Read more

“Preventing cardiovascular morbidity and mortality in cancer patients”Currently, there are over 30 million cancer survivors worldwide. Cancer survivorship is expected to grow by 30%, and it is estimated that about 2 million Australians by 2040 will be living beyond cancer. This is due to improvements in cancer screening, effective treatments and the aging of the … Read more

“The gut microbiome and neo-adjuvant immunotherapy: implications for efficacy and toxicity.”Immune checkpoint inhibitor (ICI) immunotherapies have revolutionised the treatment of melanoma, although drug resistance or concurrent immune-related adverse events (irAEs) still impact many patients. In this session the influence of the gut microbiome on clinical outcomes will be discussed using a large clinical trial cohort … Read more

Session InformationThe PREDICT program, funded by Cancer Council NSW, aims to develop a personalised chemotherapy dosing system for cancer patients to improve quality of life, reduce side effects and increase chance of survival. Current chemotherapy dosing is imprecise and not personalised. It is estimated that 20-30% of patients receiving chemotherapy will receive a dose that … Read more

Session InformationLymphodepletion chemotherapy followed by infusion of T cells that are genetically modified to express a chimeric antigen receptor (CAR) targeted to CD19 is a novel therapy for patients with relapsed and/or refractory B cell malignancies. In this seminar factors associated with outcomes of CAR-T cell therapy in adult B cell malignancies will be discussed … Read more

Session InformationThe INOVATe Study (Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care), is a major precision oncology program that has enrolled over 750 women in NSW since 2016. The goal is to facilitate recruitment to Phase I/II clinical trials of targeted cancer treatments through multi-modal molecular testing. In this Molecular Tumour … Read more

In collaboration with Sydney Health Partners and NSW Regional Health Partners, the Maridulu Budyari Gumal (SPHERE) Cancer CAG presents the October Molecular Tumour Board in our NSW Cancer Research statewide seminar series: Clinical Aspects in Adult Solid Cancers. A Molecular Tumour Board (MTB) is a multi-disciplinary forum for discussion, interpretation and communication about molecular results that may have implications for patient care. MTBs often include geneticists, bioinformaticians and molecular biologists … Read more

The concept of Precision Oncology is to optimise management for individual cancer patients based on molecular features of their disease. A Molecular Tumour Board (MTB) is a multi-disciplinary forum for discussion, interpretation and communication about molecular results that may have implications for patient care. MTBs often include geneticists, bioinformaticians and molecular biologists in addition to … Read more